Results 151 to 160 of about 6,476,358 (258)

Phase I Evaluation of Siltartoxatug, a First‐in‐Class Anti‐Tetanus Monoclonal Antibody: Safety, Pharmacokinetics and Pharmacodynamics in Healthy Australian and Chinese Populations

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Siltartoxatug, a first‐in‐class monoclonal antibody targeting tetanus toxin for post‐exposure prophylaxis, was evaluated in two phase I trials in Australian and Chinese healthy adults. In these randomized, double‐blind, placebo‐controlled, dose‐escalation studies, participants received a single intramuscular injection of siltartoxatug (10–250 μg/kg) or
Xinyu Liu   +15 more
wiley   +1 more source

Determinants of Rabies Post-Exposure Prophylaxis Compliance in Bangladesh: Informing Policy for Elimination by 2030. [PDF]

open access: yesTrop Med Infect Dis
Ghosh S   +6 more
europepmc   +1 more source

Exposure‐Response Analyses of Datopotamab Deruxtecan (Dato‐DXd), a TROP2‐Directed Antibody‐Drug Conjugate, in Advanced Non‐small Cell Lung Cancer

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Exposure‐response analyses supported a favorable benefit‐risk profile of Dato‐DXd at 6 mg/kg Q3W in patients with advanced nonsquamous NSCLC. Datopotamab deruxtecan (Dato‐DXd) is a trophoblast cell‐surface antigen‐2 (TROP2)‐directed antibody‐drug conjugate (ADC) that has demonstrated clinical activity in patients with NSCLC who have received prior ...
Ying Hong   +10 more
wiley   +1 more source

From Prediction to Decision Making: PBPK and QSP as Regulatory‐Grade NAMs

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
New approach methodologies (NAMs) encompass a diverse and rapidly evolving set of experimental and computational tools designed to generate human‐relevant mechanistic data for use in drug development and regulatory decision making. Experimental NAMs provide insights into drug disposition, pharmacological activity, and disease biology that are difficult
Karen Rowland Yeo, Piet H. van der Graaf
wiley   +1 more source

Evaluating Vaginal Microbiome Effects on Antiretroviral Exposure in the Female Genital Tract Using Pharmacometric and Machine Learning Approaches

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Antiretroviral pre‐exposure prophylaxis (PrEP) is less effective in women than expected, partly because drug exposure within the female genital tract is variable and may be influenced by the vaginal microbiome. We developed an integrated pharmacometrics and machine learning framework to evaluate associations between vaginal microbiome composition and ...
Diqin Yan   +6 more
wiley   +1 more source

Southern African HIV Clinicians Society guideline on doxycycline post-exposure prophylaxis to prevent bacterial sexually transmitted infections. [PDF]

open access: yesSouth Afr J HIV Med
Gill K   +9 more
europepmc   +1 more source

WONOEP appraisal: Biomarkers and treatment strategies beyond the synapse

open access: yesEpilepsia, EarlyView.
Abstract Epilepsy is a heterogeneous neurological disorder affecting more than 70 million people worldwide, posing significant challenges for clinicians due to its complex etiology, diverse manifestations, variable treatment responses, and the inability to predict seizures or disease onset reliably.
Mirte Scheper   +11 more
wiley   +1 more source

Completion of rabies post-exposure prophylaxis in Ouagadougou, Burkina Faso, 2021-2023: A cross-sectional analysis of routine data. [PDF]

open access: yesPLoS Negl Trop Dis
Kaboré DS   +7 more
europepmc   +1 more source

Postexposure HIV prophylaxis regimen.

open access: yes, 2005
Puro V.   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy